VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q67213907 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000329.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q67213907‏
035 ‎‡a (OCoLC)Q67213907‏
100 0 ‎‡a John G. L. Morris‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a John G. L. Morris‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a John G. L. Morris‏ ‎‡c investigador/a‏ ‎‡9 es‏
400 0 ‎‡a John G. L. Morris‏ ‎‡c investigador/a‏ ‎‡9 ast‏
670 ‎‡a Author's A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia‏
670 ‎‡a Author's A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy.‏
670 ‎‡a Author's A woman with dementia and parkinsonism unresponsive to levodopa.‏
670 ‎‡a Author's Age at onset: the major determinant of outcome in Parkinson's disease.‏
670 ‎‡a Author's An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease‏
670 ‎‡a Author's Another case of Hashimoto's encephalopathy‏
670 ‎‡a Author's Apomorphine can increase cutaneous inhibition of motor activity in Parkinson's disease‏
670 ‎‡a Author's Automatic processing dysfunction in Parkinson's disease‏
670 ‎‡a Author's Brainstem myoclonus in a patient with non-dopa-responsive parkinsonism‏
670 ‎‡a Author's Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy‏
670 ‎‡a Author's Clonic perseveration‏
670 ‎‡a Author's Clonic perseveration following thalamofrontal disconnection: a distinctive movement disorder‏
670 ‎‡a Author's Cochlear origin of hearing loss in MELAS syndrome‏
670 ‎‡a Author's Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease‏
670 ‎‡a Author's Confusion, cortical blindness and fever.‏
670 ‎‡a Author's Controversies in the treatment of Parkinson's disease‏
670 ‎‡a Author's Corticobasal syndrome with tau pathology‏
670 ‎‡a Author's Dementia in Parkinson's disease: a 20-year neuropsychological study‏
670 ‎‡a Author's Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).‏
670 ‎‡a Author's Diabetic neuropathy after pancreas transplantation: determinants of recovery.‏
670 ‎‡a Author's Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease‏
670 ‎‡a Author's Dynamics of SCR, EEG, and ERP activity in an oddball paradigm with short interstimulus intervals‏
670 ‎‡a Author's Dysfunctions of automatic‏
670 ‎‡a Author's Dysfunctions of automatic (P300a) and controlled (P300b) processing in Parkinson's disease.‏
670 ‎‡a Author's Facial sweating in Horner's syndrome‏
670 ‎‡a Author's Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.‏
670 ‎‡a Author's Hydrocephalus and structural lesions‏
670 ‎‡a Author's Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test‏
670 ‎‡a Author's Late components of the event-related potentials and their topography in Parkinson's disease‏
670 ‎‡a Author's Lesion of thalamic centromedian--parafascicular complex after chronic deep brain stimulation‏
670 ‎‡a Author's Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease‏
670 ‎‡a Author's Mitochondrial encephalomyopathy: variable clinical expression within a single kindred‏
670 ‎‡a Author's Neuropathology in the S305S tau gene mutation.‏
670 ‎‡a Author's Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies.‏
670 ‎‡a Author's Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis‏
670 ‎‡a Author's Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata‏
670 ‎‡a Author's Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations.‏
670 ‎‡a Author's Recumbent tic‏
670 ‎‡a Author's Regional brain atrophy in idiopathic parkinson's disease and diffuse Lewy body disease‏
670 ‎‡a Author's Regional brain atrophy in progressive supranuclear palsy and Lewy body disease‏
670 ‎‡a Author's Reliability of the Columbia scale for assessing signs of Parkinson's disease‏
670 ‎‡a Author's Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy‏
670 ‎‡a Author's Substantia nigra pars reticulata neurons in Parkinson's disease‏
670 ‎‡a Author's Sudomotor nerve conduction velocity and central processing time of the skin conductance response‏
670 ‎‡a Author's Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years‏
670 ‎‡a Author's The neuropsychology of de novo patients with idiopathic Parkinson's disease: the effects of age of onset.‏
670 ‎‡a Author's The progression of pathology in longitudinally followed patients with Parkinson's disease.‏
670 ‎‡a Author's The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy‏
670 ‎‡a Author's The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years‏
670 ‎‡a Author's The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa‏
670 ‎‡a Author's The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years‏
670 ‎‡a Author's The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years‏
670 ‎‡a Author's The Sydney multicentre study of Parkinson's disease. The first 18 months‏
670 ‎‡a Author's Treatment of Parkinson's disease‏
670 ‎‡a Author's Ubiquitin-positive achromatic neurons in corticobasal degeneration‏
919 ‎‡a dynamicsofscreeganderpactivityinanoddballparadigmwithshortinterstimulusintervals‏ ‎‡A Dynamics of SCR, EEG, and ERP activity in an oddball paradigm with short interstimulus intervals‏ ‎‡9 1‏
919 ‎‡a dysfunctionsofautomatic‏ ‎‡A Dysfunctions of automatic‏ ‎‡9 1‏
919 ‎‡a dysfunctionsofautomaticp300aandcontrolledp300bprocessinginparkinsonsdisease‏ ‎‡A Dysfunctions of automatic (P300a) and controlled (P300b) processing in Parkinson's disease.‏ ‎‡9 1‏
919 ‎‡a facialsweatinginhornerssyndrome‏ ‎‡A Facial sweating in Horner's syndrome‏ ‎‡9 1‏
919 ‎‡a frontalatrophycorrelateswithbehaviouralchangesinprogressivesupranuclearpalsy‏ ‎‡A Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.‏ ‎‡9 1‏
919 ‎‡a hydrocephalusandstructurallesions‏ ‎‡A Hydrocephalus and structural lesions‏ ‎‡9 1‏
919 ‎‡a identifyingthepatternofolfactorydeficitsinparkinsondiseaseusingthebriefsmellidentificationtest‏ ‎‡A Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test‏ ‎‡9 1‏
919 ‎‡a latecomponentsoftheeventrelatedpotentialsandtheirtopographyinparkinsonsdisease‏ ‎‡A Late components of the event-related potentials and their topography in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a lesionofthalamiccentromedianparafascicularcomplexafterchronicdeepbrainstimulation‏ ‎‡A Lesion of thalamic centromedian--parafascicular complex after chronic deep brain stimulation‏ ‎‡9 1‏
919 ‎‡a midbrainneuropathologyinidiopathicparkinsonsdiseaseanddiffuselewybodydisease‏ ‎‡A Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease‏ ‎‡9 1‏
919 ‎‡a mitochondrialencephalomyopathyvariableclinicalexpressionwithinasinglekindred‏ ‎‡A Mitochondrial encephalomyopathy: variable clinical expression within a single kindred‏ ‎‡9 1‏
919 ‎‡a neuropathologyinthes305staugenemutation‏ ‎‡A Neuropathology in the S305S tau gene mutation.‏ ‎‡9 1‏
919 ‎‡a neuropathologyof3clinicalcasesprospectivelydiagnosedasdementiawithlewybodies‏ ‎‡A Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies.‏ ‎‡9 1‏
919 ‎‡a neuroradiologicalfeaturesof6kindredswithmelastrnaleua2343gpointmutationimplicationsforpathogenesis‏ ‎‡A Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis‏ ‎‡9 1‏
919 ‎‡a progressivesupranuclearpalsyaffectsboththesubstantianigraparscompactaandreticulata‏ ‎‡A Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata‏ ‎‡9 1‏
919 ‎‡a progressivesupranuclearpalsypathologycausedbyanovelsilentmutationinexon10ofthetaugeneexpansionofthediseasephenotypecausedbytaugenemutations‏ ‎‡A Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations.‏ ‎‡9 1‏
919 ‎‡a recumbenttic‏ ‎‡A Recumbent tic‏ ‎‡9 1‏
919 ‎‡a regionalbrainatrophyinidiopathicparkinsonsdiseaseanddiffuselewybodydisease‏ ‎‡A Regional brain atrophy in idiopathic parkinson's disease and diffuse Lewy body disease‏ ‎‡9 1‏
919 ‎‡a regionalbrainatrophyinprogressivesupranuclearpalsyandlewybodydisease‏ ‎‡A Regional brain atrophy in progressive supranuclear palsy and Lewy body disease‏ ‎‡9 1‏
919 ‎‡a reliabilityofthecolumbiascaleforassessingsignsofparkinsonsdisease‏ ‎‡A Reliability of the Columbia scale for assessing signs of Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a retroperitonealfibrosisskinandpleuropulmonarychangesassociatedwithbromocriptinetherapy‏ ‎‡A Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy‏ ‎‡9 1‏
919 ‎‡a substantianigraparsreticulataneuronsinparkinsonsdisease‏ ‎‡A Substantia nigra pars reticulata neurons in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a sudomotornerveconductionvelocityandcentralprocessingtimeoftheskinconductanceresponse‏ ‎‡A Sudomotor nerve conduction velocity and central processing time of the skin conductance response‏ ‎‡9 1‏
919 ‎‡a sydneymulticenterstudyofparkinsonsdiseasenon50doparesponsiveproblemsdominateat15years‏ ‎‡A Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years‏ ‎‡9 1‏
919 ‎‡a neuropsychologyofdenovopatientswithidiopathicparkinsonsdiseasetheeffectsofageofonset‏ ‎‡A The neuropsychology of de novo patients with idiopathic Parkinson's disease: the effects of age of onset.‏ ‎‡9 1‏
919 ‎‡a progressionofpathologyinlongitudinallyfollowedpatientswithparkinsonsdisease‏ ‎‡A The progression of pathology in longitudinally followed patients with Parkinson's disease.‏ ‎‡9 1‏
919 ‎‡a subthalamicnucleusinparkinsonsdiseaseandprogressivesupranuclearpalsy‏ ‎‡A The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy‏ ‎‡9 1‏
919 ‎‡a sydneymulticenterstudyofparkinsonsdiseasetheinevitabilityofdementiaat20years‏ ‎‡A The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years‏ ‎‡9 1‏
919 ‎‡a sydneymulticentrestudyofparkinsonsdiseasearandomisedprospective5yearstudycomparinglowdosebromocriptinewithlowdoselevodopacarbidopa‏ ‎‡A The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa‏ ‎‡9 1‏
919 ‎‡a sydneymulticentrestudyofparkinsonsdiseaseareportonthe13years‏ ‎‡A The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years‏ ‎‡9 1‏
919 ‎‡a sydneymulticentrestudyofparkinsonsdiseaseprogressionandmortalityat10years‏ ‎‡A The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years‏ ‎‡9 1‏
919 ‎‡a sydneymulticentrestudyofparkinsonsdiseasethe118months‏ ‎‡A The Sydney multicentre study of Parkinson's disease. The first 18 months‏ ‎‡9 1‏
919 ‎‡a treatmentofparkinsonsdisease‏ ‎‡A Treatment of Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a ubiquitinpositiveachromaticneuronsincorticobasaldegeneration‏ ‎‡A Ubiquitin-positive achromatic neurons in corticobasal degeneration‏ ‎‡9 1‏
919 ‎‡a diabeticneuropathyafterpancreastransplantationdeterminantsofrecovery‏ ‎‡A Diabetic neuropathy after pancreas transplantation: determinants of recovery.‏ ‎‡9 1‏
919 ‎‡a dementiainparkinsonsdiseasea20yearneuropsychologicalstudysydneymulticentrestudy‏ ‎‡A Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).‏ ‎‡9 1‏
919 ‎‡a dementiainparkinsonsdiseasea20yearneuropsychologicalstudy‏ ‎‡A Dementia in Parkinson's disease: a 20-year neuropsychological study‏ ‎‡9 1‏
919 ‎‡a corticobasalsyndromewithtaupathology‏ ‎‡A Corticobasal syndrome with tau pathology‏ ‎‡9 1‏
919 ‎‡a controversiesinthetreatmentofparkinsonsdisease‏ ‎‡A Controversies in the treatment of Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a confusioncorticalblindnessandfever‏ ‎‡A Confusion, cortical blindness and fever.‏ ‎‡9 1‏
919 ‎‡a comparisonofmotorcognitiveandbehavioralfeaturesinprogressivesupranuclearpalsyandparkinsonsdisease‏ ‎‡A Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a cochlearoriginofhearinglossinmelassyndrome‏ ‎‡A Cochlear origin of hearing loss in MELAS syndrome‏ ‎‡9 1‏
919 ‎‡a clonicperseverationfollowingthalamofrontaldisconnectionadistinctivemovementdisorder‏ ‎‡A Clonic perseveration following thalamofrontal disconnection: a distinctive movement disorder‏ ‎‡9 1‏
919 ‎‡a clonicperseveration‏ ‎‡A Clonic perseveration‏ ‎‡9 1‏
919 ‎‡a clinicaldeficitscorrelatewithregionalcerebralatrophyinprogressivesupranuclearpalsy‏ ‎‡A Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy‏ ‎‡9 1‏
919 ‎‡a brainstemmyoclonusinapatientwithnondoparesponsiveparkinsonism‏ ‎‡A Brainstem myoclonus in a patient with non-dopa-responsive parkinsonism‏ ‎‡9 1‏
919 ‎‡a automaticprocessingdysfunctioninparkinsonsdisease‏ ‎‡A Automatic processing dysfunction in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a apomorphinecanincreasecutaneousinhibitionofmotoractivityinparkinsonsdisease‏ ‎‡A Apomorphine can increase cutaneous inhibition of motor activity in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a anothercaseofhashimotosencephalopathy‏ ‎‡A Another case of Hashimoto's encephalopathy‏ ‎‡9 1‏
919 ‎‡a australianmulticentreopenlabelstudyofpergolideasanadjuncttolevodopainparkinsonsdisease‏ ‎‡A An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a ageatonsetthemajordeterminantofoutcomeinparkinsonsdisease‏ ‎‡A Age at onset: the major determinant of outcome in Parkinson's disease.‏ ‎‡9 1‏
919 ‎‡a womanwithdementiaandparkinsonismunresponsivetolevodopa‏ ‎‡A A woman with dementia and parkinsonism unresponsive to levodopa.‏ ‎‡9 1‏
919 ‎‡a roleforthesubstantianigraparsreticulatainthegazepalsyofprogressivesupranuclearpalsy‏ ‎‡A A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy.‏ ‎‡9 1‏
919 ‎‡a longitudinalofparkinsonsdiseaseclinicalandneuropsychologicalcorrelatesofdementia‏ ‎‡A A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia‏ ‎‡9 1‏
919 ‎‡a diffuselewybodydiseaseclinicalfeaturesin9caseswithoutcoexistentalzheimersdisease‏ ‎‡A Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000430462353‏
996 ‎‡2 CAOONL|ncf11022196‏
996 ‎‡2 DNB|1052515762‏
996 ‎‡2 JPG|500002198‏
996 ‎‡2 BIBSYS|9000539‏
996 ‎‡2 BNF|12021180‏
996 ‎‡2 ISNI|0000000114726679‏
996 ‎‡2 NUKAT|n 2015226799‏
996 ‎‡2 LC|no2004091253‏
996 ‎‡2 LC|no2016087360‏
996 ‎‡2 ISNI|0000000031111388‏
996 ‎‡2 ISNI|0000000062122346‏
996 ‎‡2 ISNI|0000000040987111‏
996 ‎‡2 LC|no2014029124‏
996 ‎‡2 J9U|987007324573605171‏
996 ‎‡2 ISNI|0000000001391585‏
996 ‎‡2 J9U|987007436713805171‏
996 ‎‡2 NUKAT|n 2010079884‏
996 ‎‡2 ISNI|0000000442538204‏
996 ‎‡2 ISNI|0000000072922531‏
996 ‎‡2 BIBSYS|90056480‏
996 ‎‡2 PLWABN|9813992255105606‏
996 ‎‡2 BIBSYS|4109580‏
996 ‎‡2 ISNI|0000000033601946‏
996 ‎‡2 ISNI|0000000115598939‏
996 ‎‡2 ISNI|000000011655185X‏
996 ‎‡2 LC|n 89612207‏
996 ‎‡2 ISNI|0000000060590218‏
996 ‎‡2 NTA|068208251‏
996 ‎‡2 RERO|A012531720‏
996 ‎‡2 SUDOC|200389637‏
996 ‎‡2 ISNI|0000000374436926‏
996 ‎‡2 NKC|xx0232634‏
996 ‎‡2 LC|no2014006102‏
996 ‎‡2 PTBNP|892465‏
996 ‎‡2 BIBSYS|90134051‏
996 ‎‡2 BLBNB|000547582‏
996 ‎‡2 SIMACOB|14752867‏
996 ‎‡2 LC|n 79044447‏
996 ‎‡2 CAOONL|ncf10333945‏
996 ‎‡2 DNB|1020637811‏
996 ‎‡2 LC|n 86856796‏
996 ‎‡2 ISNI|0000000383302014‏
996 ‎‡2 ISNI|0000000032798839‏
996 ‎‡2 LC|n 2023015072‏
996 ‎‡2 ISNI|0000000050503926‏
996 ‎‡2 J9U|987007364430405171‏
996 ‎‡2 NTA|070816670‏
996 ‎‡2 ISNI|0000000078066086‏
996 ‎‡2 LC|nb2001083450‏
996 ‎‡2 LC|n 2021046904‏
996 ‎‡2 NUKAT|n 2002067308‏
996 ‎‡2 RERO|A012322911‏
996 ‎‡2 LC|nb2009014717‏
996 ‎‡2 LC|n 85054972‏
996 ‎‡2 LC|no2016060674‏
996 ‎‡2 CAOONL|ncf11541234‏
996 ‎‡2 NTA|109863097‏
996 ‎‡2 RERO|A012453047‏
996 ‎‡2 LC|n 82013481‏
996 ‎‡2 RERO|A012357498‏
996 ‎‡2 DNB|138432392‏
996 ‎‡2 LC|nb2008014430‏
996 ‎‡2 LC|n 2007161707‏
996 ‎‡2 LC|n 2024013265‏
996 ‎‡2 NII|DA01219772‏
996 ‎‡2 NUKAT|nx2022805670‏
996 ‎‡2 DBC|87097969615058‏
996 ‎‡2 BNC|981060980784506706‏
996 ‎‡2 ISNI|0000000063004296‏
996 ‎‡2 LC|n 80011183‏
996 ‎‡2 NKC|mub2014812046‏
996 ‎‡2 LC|n 2010079916‏
996 ‎‡2 CAOONL|ncf11543052‏
996 ‎‡2 SUDOC|082613419‏
996 ‎‡2 NTA|202959511‏
996 ‎‡2 RERO|A000116164‏
996 ‎‡2 LC|n 87119359‏
996 ‎‡2 LC|n 2018058356‏
996 ‎‡2 NLA|000035744317‏
996 ‎‡2 SUDOC|25781213X‏
996 ‎‡2 SUDOC|277424496‏
996 ‎‡2 DNB|124623921‏
996 ‎‡2 NDL|00795869‏
996 ‎‡2 NUKAT|n 2018130095‏
996 ‎‡2 ISNI|0000000457005494‏
996 ‎‡2 BNF|13957394‏
996 ‎‡2 BNF|10590316‏
996 ‎‡2 LC|n 91125874‏
996 ‎‡2 LC|no2021046582‏
996 ‎‡2 LC|n 2011184368‏
996 ‎‡2 DNB|11692991X‏
996 ‎‡2 BIBSYS|11011925‏
996 ‎‡2 ISNI|0000000047741819‏
996 ‎‡2 N6I|vtls001323361‏
996 ‎‡2 CAOONL|ncf10227831‏
996 ‎‡2 LC|n 96119769‏
996 ‎‡2 CAOONL|ncf11482670‏
996 ‎‡2 PLWABN|9810574581005606‏
996 ‎‡2 BIBSYS|90348798‏
996 ‎‡2 LC|n 87152273‏
996 ‎‡2 ISNI|000000012397851X‏
996 ‎‡2 LC|n 89665362‏
996 ‎‡2 BNF|13527021‏
996 ‎‡2 LC|n 98102473‏
996 ‎‡2 CAOONL|ncf10114542‏
996 ‎‡2 LC|n 95116866‏
996 ‎‡2 BNC|981058528691806706‏
996 ‎‡2 CAOONL|ncf10268500‏
996 ‎‡2 ISNI|0000000434904390‏
996 ‎‡2 ISNI|0000000121443570‏
996 ‎‡2 DNB|173518737‏
996 ‎‡2 DNB|135540356‏
996 ‎‡2 PLWABN|9810651568705606‏
996 ‎‡2 BIBSYS|99013033‏
996 ‎‡2 NTA|074835238‏
996 ‎‡2 LC|nb2008014344‏
996 ‎‡2 J9U|987007270530205171‏
996 ‎‡2 NUKAT|n 01042312‏
996 ‎‡2 LC|n 95000041‏
996 ‎‡2 BNF|14208884‏
996 ‎‡2 BNF|14208885‏
996 ‎‡2 BNF|14208886‏
996 ‎‡2 LC|n 81013284‏
996 ‎‡2 ISNI|0000000501721405‏
996 ‎‡2 DNB|1145969518‏
996 ‎‡2 ISNI|0000000450987069‏
996 ‎‡2 LC|nr2004029682‏
996 ‎‡2 ISNI|0000000025007066‏
996 ‎‡2 NUKAT|n 2020000518‏
996 ‎‡2 DNB|1159932646‏
996 ‎‡2 BNF|13330465‏
996 ‎‡2 LC|no2015148905‏
996 ‎‡2 ISNI|0000000418944886‏
996 ‎‡2 NLA|000035363549‏
996 ‎‡2 DNB|171734149‏
996 ‎‡2 NTA|168282372‏
996 ‎‡2 BAV|495_301781‏
996 ‎‡2 SUDOC|15817237X‏
996 ‎‡2 NUKAT|n 2015144036‏
996 ‎‡2 BAV|495_163690‏
996 ‎‡2 J9U|987008729375005171‏
996 ‎‡2 ISNI|0000000084712224‏
996 ‎‡2 ISNI|0000000080479752‏
996 ‎‡2 BNF|12554934‏
996 ‎‡2 RERO|A011553311‏
996 ‎‡2 ISNI|0000000364797963‏
996 ‎‡2 NTA|241478758‏
996 ‎‡2 ISNI|0000000140882907‏
996 ‎‡2 NUKAT|n 2010306257‏
996 ‎‡2 SUDOC|197844960‏
996 ‎‡2 LC|nb2016024745‏
996 ‎‡2 LC|no2006019096‏
996 ‎‡2 J9U|987007432044305171‏
996 ‎‡2 N6I|vtls000075193‏
996 ‎‡2 N6I|vtls000326237‏
996 ‎‡2 J9U|987008729759705171‏
996 ‎‡2 LC|n 91037521‏
996 ‎‡2 ISNI|0000000054654932‏
996 ‎‡2 BIBSYS|7042604‏
996 ‎‡2 NII|DA1597174X‏
996 ‎‡2 J9U|987007344826105171‏
996 ‎‡2 NLA|000036010577‏
996 ‎‡2 LC|n 2006059152‏
996 ‎‡2 LC|no2003075868‏
996 ‎‡2 NLA|000035874522‏
996 ‎‡2 N6I|vtls000045354‏
996 ‎‡2 DNB|136094066‏
996 ‎‡2 LC|n 93804170‏
996 ‎‡2 PLWABN|9812829859205606‏
996 ‎‡2 LC|nb2017007274‏
996 ‎‡2 J9U|987007352384505171‏
996 ‎‡2 BNF|15014818‏
996 ‎‡2 PLWABN|9810589419905606‏
996 ‎‡2 RERO|A012369373‏
996 ‎‡2 LC|no2008094562‏
996 ‎‡2 NUKAT|n 2017034952‏
996 ‎‡2 ISNI|0000000049927692‏
996 ‎‡2 ISNI|0000000084109302‏
996 ‎‡2 BNF|10507389‏
996 ‎‡2 ISNI|0000000081211256‏
996 ‎‡2 ISNI|0000000081735527‏
996 ‎‡2 BNF|14456190‏
996 ‎‡2 DNB|118584235‏
996 ‎‡2 BNF|14496294‏
996 ‎‡2 DNB|1104291908‏
996 ‎‡2 NII|DA19697617‏
996 ‎‡2 LC|no2012012672‏
996 ‎‡2 LC|n 50016844‏
996 ‎‡2 CAOONL|ncf10336366‏
996 ‎‡2 ISNI|0000000031235225‏
996 ‎‡2 PLWABN|9810556717805606‏
996 ‎‡2 NKC|xx0231150‏
996 ‎‡2 CAOONL|ncf11306261‏
996 ‎‡2 LC|no 99032065‏
996 ‎‡2 LC|nr 95033363‏
996 ‎‡2 CAOONL|ncf11072592‏
996 ‎‡2 ISNI|0000000049652537‏
996 ‎‡2 NUKAT|n 98031289‏
996 ‎‡2 CAOONL|ncf11574652‏
996 ‎‡2 LC|no2019092993‏
996 ‎‡2 BIBSYS|2016192‏
996 ‎‡2 LC|no2010099587‏
996 ‎‡2 ISNI|0000000356938770‏
996 ‎‡2 NKC|jo2006321108‏
996 ‎‡2 SUDOC|085857106‏
996 ‎‡2 ISNI|0000000114768078‏
996 ‎‡2 LC|no2006064300‏
996 ‎‡2 NDL|00542674‏
996 ‎‡2 DNB|1261807472‏
996 ‎‡2 RERO|A003610988‏
996 ‎‡2 SUDOC|131380974‏
996 ‎‡2 SUDOC|081198914‏
996 ‎‡2 LC|nb2001049137‏
996 ‎‡2 SUDOC|251581500‏
996 ‎‡2 ISNI|0000000076821383‏
996 ‎‡2 NUKAT|n 2022221917‏
996 ‎‡2 ISNI|0000000041355255‏
996 ‎‡2 ISNI|000000049618953X‏
996 ‎‡2 LC|n 82044160‏
996 ‎‡2 LC|n 2021032252‏
996 ‎‡2 NTA|341363642‏
996 ‎‡2 NUKAT|n 2004087014‏
996 ‎‡2 DNB|121036227‏
996 ‎‡2 NII|DA17839925‏
996 ‎‡2 NTA|074417525‏
996 ‎‡2 ISNI|000000002485081X‏
996 ‎‡2 LC|n 79135286‏
996 ‎‡2 LC|no 88002494‏
996 ‎‡2 LC|n 2004096774‏
996 ‎‡2 NII|DA09130708‏
996 ‎‡2 NUKAT|n 2003060599‏
996 ‎‡2 NTA|068737092‏
996 ‎‡2 J9U|987007344173605171‏
996 ‎‡2 PTBNP|162223‏
996 ‎‡2 DNB|17351877X‏
996 ‎‡2 BIBSYS|15037072‏
996 ‎‡2 JPG|500031274‏
996 ‎‡2 JPG|500031273‏
996 ‎‡2 ISNI|0000000446434453‏
996 ‎‡2 J9U|987007347487405171‏
996 ‎‡2 LC|n 2004084086‏
996 ‎‡2 LC|no2015091646‏
996 ‎‡2 LC|n 85348743‏
996 ‎‡2 DNB|1155311914‏
996 ‎‡2 CAOONL|ncf12091240‏
996 ‎‡2 NUKAT|n 2021105756‏
996 ‎‡2 ISNI|0000000049489055‏
996 ‎‡2 LC|n 2001108119‏
996 ‎‡2 LC|n 2006082596‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏